Online pharmacies will now have to employ stricter checks to stop people who are already a healthy weight or have a history ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

A new poll from The Associated Press-NORC Center for Public Affairs Research shows about half of U.S. adults believe it is a ...

Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...

New industry rules require visual size checks or GP medical records for online fat jab purchases. The updated guidelines ...

More than 69.2 million FDA-approved weight-loss prescriptions were dispensed in the U.S. from July 2017 through February 2024 ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

The pharmacy regulator is working with other bodies to jointly tackle inappropriate advertising and promotions of the drugs ...

The General Pharmaceutical Council (GPhC) has introduced new rules for weight-loss jabs, such as Wegovy and Mounjaro, in ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...